scispace - formally typeset
R

Richard Zhang

Researcher at Pfizer

Publications -  44
Citations -  2289

Richard Zhang is an academic researcher from Pfizer. The author has contributed to research in topics: Donepezil & Tofacitinib. The author has an hindex of 20, co-authored 44 publications receiving 2047 citations.

Papers
More filters
Journal ArticleDOI

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD

TL;DR: It remains puzzling to me why the investigators restricted the entry criteria and consequently selected a population that was not representative of general clinical practice when excluding patients with frequently coexisting medical conditions such as diabetes, chronic obstructive pulmonary disease, and endocrine diseases.
Journal ArticleDOI

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Roy Fleischmann, +212 more
- 29 Jul 2017 - 
TL;DR: Tofacitinib monotherapy was not shown to be non-inferior to either combination of adalimumab and methotrexate, and no new or unexpected safety issues were reported for either treatment in this study for up to 1 year.
Journal ArticleDOI

3-Year Study of Donepezil Therapy in Alzheimer’s Disease: Effects of Early and Continuous Therapy

TL;DR: Patients in whom the start of treatment is delayed may demonstrate slightly reduced benefits as compared with those seen in patients starting donepezil therapy early in the course of Alzheimer’s disease, and data support the long-term efficacy and safety ofdonepezil.
Journal ArticleDOI

Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders

TL;DR: The results of these analyses suggest that donepezil reduces behavioral symptoms, particularly mood disturbances and delusions, in patients with AD with relatively severe psychopathology.
Journal ArticleDOI

A multinational, randomised, 12‐week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease

TL;DR: To compare directly, in the same patient cohort, the ease of use and tolerability of donepezil and galantamine in the treatment of Alzheimer's disease (AD), and investigate the effects of both treatments on cognition and activities of daily living (ADL).